Company ProfilePremium

Covestro AG

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Covestro AG - Chemicals & Materials showcase

Year Founded & Workforce

2005

17,600 Employees

Industry

Chemicals & Materials

Services

ProductCast ElastomerPolycarbonate panelsGlobal Textile Coatings
Covestro AG logo

Covestro AG Employee Contacts

503 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Covestro AG Overview

Covestro is one of the world's largest producers of high-performance polymer materials and their precursors, built on Bayer's eight-decade legacy in polyurethane and polycarbonate chemistry. It sits in the upstream-to-midstream portion of the chemical value chain, converting petrochemical (and increasingly bio-based and recycled) feedstocks into isocyanates (MDI, TDI, HDI and aliphatic derivatives), polyols, polycarbonate resins and specialty systems for coatings, adhesives, elastomers and films. Roughly half of revenue comes from scale-driven commodity-like "Performance Materials" and half from customer-specific "Solutions & Specialties". After three years of cyclical trough (sales down from €18.0bn in 2022 to €12.9bn in 2025 and net losses each year), Covestro was acquired by ADNOC's international chemicals vehicle XRG in a ~€14.7bn transaction completed in late 2025, giving it a deep-pocketed, feedstock-integrated strategic owner. Its strategic thesis is "Sustainable Future": leadership in circular, climate-neutral polymers, now combined with Gulf-based capacity growth.


What the company does

Covestro manufactures polymer materials and components. Its chemistry falls into three technology families:

  1. Polyurethanes (PU) — isocyanates (MDI for rigid foams, TDI for flexible foams) and polyether polyols, sold to foam makers for insulation (construction, refrigeration/cold chain) and comfort (furniture, mattresses, automotive seating).

  2. Polycarbonates (PC) — engineering thermoplastic (Makrolon® brand) and compounds/blends (Bayblend®, Makroblend®) for automotive, electrical & electronics, healthcare, lighting and construction glazing.

  3. Coatings, Adhesives & Specialties — aliphatic isocyanates and derivatives (HDI, IPDI, H12MDI; Desmodur®), polyols/resins (Desmophen®, Bayhydrol®), the former DSM Resins & Functional Materials portfolio (NeoCryl®, NeoRez®, Decovery®), thermoplastic polyurethanes (Desmopan®), elastomers, and specialty films (Makrofol®, Platilon®).

Business model and revenue model

Product sales ≈ ~100% of revenue: Covestro does not report material service, subscription or licensing revenue; technology licensing and engineering services are incidental (n/d as a separate line).

Performance Materials: behaves as a cost-leadership, scale business with prices set by global supply/demand for MDI/TDI/polyols/PC; margins swing sharply with industry utilisation and raw material (benzene, toluene, propylene, chlorine, natural gas, energy) spreads.

Solutions & Specialties: is a formulation- and application-driven business: tailored grades, technical service, co-development with OEMs, stickier pricing and higher, more stable margins.

Value-chain position

Upstream: buys aromatics (benzene, toluene), propylene, natural gas/energy, chlorine (partly produced in-house via chlor-alkali electrolysis), phenol/acetone/bisphenol A inputs. Midstream: isocyanate, polyol and PC production at large integrated "world-scale" sites (Leverkusen, Dormagen, Krefeld-Uerdingen, Antwerp, Baytown, Shanghai, Tarragona, Map Ta Phut). Downstream: sells mostly B2B to converters (foam producers, compounders, coaters, adhesive formulators) and OEMs.

Customer types and end-markets

Covestro's largest end-markets (historically disclosed shares; latest split n/v) are construction (insulation, floor coatings), automotive & transportation (seating, interiors, lighting, coatings, e-mobility battery housings), furniture & wood processing (mattresses, wood coatings), electrical & electronics (housings, displays), sports & leisure, cosmetics, healthcare (medical-grade PC and TPU), and chemicals/industrial.

Company self-description (latest annual reporting, paraphrased)

Covestro describes itself as one of the world's leading manufacturers of high-quality polymer materials and their components, pursuing a vision of becoming fully circular and supporting customers' sustainability goals ("Sustainable Future" strategy). Every investor release in 2026 closes with: sales €12.9bn in FY2025, 46 production sites, ~17,600 FTE.

Independent characterisation

Covestro is fundamentally a cyclical isocyanates/polycarbonate producer with a growing specialty overlay. Its earnings power is dominated by MDI and PC margins, which collapsed in 2022–2025 due to Chinese capacity additions (notably Wanhua), weak European construction, high German energy costs and soft durable-goods demand. Its strategic differentiators are (a) technology leadership and process efficiency in MDI/TDI/PC, (b) one of the broadest aliphatic isocyanate franchises globally (coatings & adhesives), and (c) an early-mover position in circular feedstocks (chemical recycling of PU foam and PC, bio-attributed MDI/PC). Under XRG ownership, the investment case shifts from public-market equity story to an integrated Gulf-feedstock growth platform, evidenced by the July 2026 MDI expansion program in China and the UAE.

Strategy

Corporate strategy — "Sustainable Future" (launched 2023): become fully circular; focus on growth in sustainable solutions; climate-neutral operations (Scope 1 & 2) by 2035; Scope 3 by 2050 (targets n/v in detail).

Key initiatives (last 24 months)

Guidance (FY2026, as of 9 July 2026 / H1 report)

Medium-term targets as a listed company are no longer published.

Products & Services

Performance Materials

Product lineDescription / capabilitiesTarget customersFlagship / notes
MDI (methylene diphenyl diisocyanate)Isocyanate for rigid PU foam, binders, elastomersInsulation panel makers, appliance (refrigeration) OEMs, constructionDesmodur® 44 series; world-scale plants Brunsbüttel, Krefeld-Uerdingen, Tarragona, Baytown, Shanghai; ~660 kt expansion program (China/UAE) announced July 2026
TDI (toluene diisocyanate)Isocyanate for flexible slabstock and molded foamMattress, furniture, automotive seat makersGas-phase phosgenation technology (Dormagen, Shanghai)
Polyether polyolsReactive partner for isocyanatesFoam producersArcol®/Desmophen® grades; Dormagen polyols affected by Rhine low-water force majeure (2026)
Standard polycarbonate resinTransparent, impact-resistant thermoplasticCompounders, sheet/film producers, E&E, automotiveMakrolon® base grades
CO2-based / bio-attributed materialsPolyols made partly from CO2 (cardyon®); mass-balance bio-circular MDI/PC (ISCC PLUS)Brands with Scope 3 targetscardyon® launched 2016; "CQ" product label for circular-attributed products
Chlorine & co-productsChlor-alkali for captive phosgene/isocyanate chainInternal use; some external salesOxygen-depolarised cathode technology

Solutions & Specialties

Product lineDescription / capabilitiesTarget customersFlagship / notes
Aliphatic isocyanates (HDI, IPDI, H12MDI, PDI)Light-stable crosslinkers for high-performance PU coatingsAutomotive OEM/refinish, industrial, marine, wood coatings formulatorsDesmodur® N; Desmodur® eco N (partly bio-based PDI); capacity extended by Vencorex Rayong & Freeport sites (July 2026)
Coating polyols & dispersionsWaterborne and solvent-borne resinsCoatings formulatorsDesmophen®, Bayhydrol®, Bayhydur®
Former DSM RFM resinsWaterborne acrylics, urethane dispersions, powder coating resins, bio-based resins, functional materials (optical fibre coatings, additive manufacturing resins)Decorative and industrial coatings, graphic artsNeoCryl®, NeoRez®, Decovery®, Uralac® (powder), Niaga® (circular design) — acquired April 2021
Adhesives raw materialsPolyurethane dispersions and prepolymersFootwear, automotive interior, packaging adhesivesDispercoll® U
Engineering plastics (PC compounds and blends)PC/ABS, PC/PBT, flame-retardant and medical gradesAutomotive lighting/interiors, E&E housings, EV battery components, healthcareBayblend®, Makroblend®, Makrolon® specialty and Rx medical grades; Apec® high-heat PC
Thermoplastic polyurethane (TPU)Elastomeric, abrasion-resistantFootwear, sports, cables, 3D printingDesmopan®, Texin®
Elastomers & tailored urethanesCast elastomers, PU systemsIndustrial rollers, mining, automotiveBaytec®, Vulkollan®
Specialty filmsPC and TPU films for ID cards, displays, medical, electronicsSecurity documents, electronicsMakrofol®, Platilon®
Systems housesFormulated PU systems for insulation, CASERegional convertersRegional system houses (network size n/v)

Pricing models are not disclosed; sales are predominantly contract and spot pricing linked to market indices for PM, and negotiated, value-based pricing for S&S. Product launch years beyond those noted are n/v.

Financial Narrative

Income statement

Sources: Covestro Annual Reports 2021–2025 and FY press releases. FY2024 and FY2025 figures verified against AR 2025 ("Results of Operations, Financial Position and Net Assets"). Revenue CAGR FY2021–FY2025: –5.0% p.a. (derived).

Commentary. Covestro's P&L shows a classic commodity-chemical down-cycle. 2021 marked a cyclical peak (EBITDA margin ~19%), driven by post-COVID restocking and tight MDI/PC markets. In 2022 record sales were price-inflated (energy/raw-material pass-through), but margins collapsed and impairments pushed net income negative. 2023–2025 saw both price deflation (sales –28% from 2022 to 2025) and margin compression. FY2025 was the trough: EBITDA –30.9% to €740m, EBIT –€347m and net loss –€644m, driven by lower selling prices across all regions, FX headwinds, the Dormagen fire, and higher D&A/impairments (€1,087m). Management had initially guided €1.0–1.6bn EBITDA for 2025 and cut to €700–800m on 30 Oct 2025.

Quarterly bridge FY2025

Q2 and Q3 sales rounded as released (€3.4bn; €3.2bn); Q1 sales derived as residual and therefore approximate. Q1 EBITDA derived from H1 2025 EBITDA (€407m) less Q2 (€270m). Note: quarterly net income sums to –€678m vs. FY –€644m reported — the €34m discrepancy likely reflects rounding/restatement or attribution differences and is flagged unresolved.

H1 2026 performance (Half-Year Financial Report 2026)

H1 2025 sales derived from quarterly figures above (approximate). EBITDA rose 64.4% on higher selling prices with raw-material costs lagging; FX was a headwind. Net income turned positive (€120m).

Balance sheet and cash flow

Dividends paid: €0 for FY2022–FY2025 (dividend suspended); buybacks: none since the €1.5bn programme of 2022 was halted (n/v detail).

Commentary. The €1.17bn capital increase subscribed by XRG at closing is the dominant driver of the 31% fall in net financial debt to €1,796m despite negative free operating cash flow. The large FY2025 investing outflow (€1.3bn) likely reflects placement of capital-increase proceeds into short-term financial investments (breakdown n/v). Capex was held flat at ~€0.8bn — high relative to depressed EBITDA (capex/EBITDA >100% in FY2025).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsPrincipal products

Performance Materials (PM)

Standardised, high-volume materials

MDI, TDI, polyether polyols, standard polycarbonate resins, chlorine/precursors

Solutions & Specialties (S&S)

Customised, application-intensive materials

Coatings & adhesives raw materials (aliphatic isocyanates, resins, DSM RFM portfolio), engineering plastics (PC compounds/blends), tailored urethanes (TPU, elastomers, systems), specialty films

All other / reconciliation

Corporate functions, intersegment eliminations, other businesses

—

Revenue by Segment

SegmentFY2023FY2024FY2025

Performance Materials sales (EUR Mn)

n/v

6,9406,100

Solutions & Specialties sales (EUR Mn)

7,3007,0006,600

Group sales (EUR Mn)

14,37714,17912,942

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

SegmentFY2023FY2024FY2025

Solutions & Specialties EBITDA (EUR Mn)

817740681

Performance Materials EBITDA (EUR Mn)

Performance Materials EBITDA (EUR Mn)n/vn/vn/v

Group EBITDA (EUR Mn)

1,0801,071740

Results by Segment (Half-Yearly)

SegmentH1 2025H1 2026

Performance Materials EBITDA (EUR Mn)

162334

Solutions & Specialties EBITDA (EUR Mn)

356465

All other segments EBITDA (EUR Mn)

2411

Reconciliation EBITDA (EUR Mn)

-135-141

Group EBITDA (EUR Mn)

407669

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Sales (EUR Mn)

15,90317,96814,37714,17912,942

EBITDA (EUR Mn)

3,0701,6171,0801,071740

Depreciation amortisation and impairments (EUR Mn)

n/v

n/v

n/v

9841,087

EBIT (EUR Mn)

n/v

n/v

n/v

87-347

Financial result (EUR Mn)

n/v

n/v

n/v

-114-145

Net income (EUR Mn)

1,616-272-198-266-644

EPS basic (EUR)

8.37-1.42-1.05

n/v

n/v

Dividend per share (EUR)

3.400000

EBITDA margin (%)

19.39.07.57.65.7

Net margin (%)

10.2-1.5-1.4-1.9-5.0

Income Statement

MetricQ1 2025Q2 2025Q3 2025Q4 2025

Sales (EUR Mn)

3,4273,4003,2002,915

EBITDA (EUR Mn)

13727024291

Net income (EUR Mn)

-160-59-47-412

Free operating cash flow (EUR Mn)

-253-22811187

Income Statement (Half-Yearly)

MetricH1 2025H1 2026

Sales (EUR Mn)

6,8276,729

EBITDA (EUR Mn)

407669

EBIT (EUR Mn)

-48244

Net income attributable (EUR Mn)

-219120

Cash Flow and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (EUR Mn)

n/v

n/v

n/v

870487

Capex PPE and intangibles (EUR Mn)

n/v

n/v

n/v

781770

Free operating cash flow (EUR Mn)

1,46337723289-283

Net investing cash flow (EUR Mn)

n/v

n/v

n/v

-423-1,295

Net financing cash flow (EUR Mn)

n/v

n/v

n/v

-565968

Net financial debt (EUR Mn)

n/v

n/v

n/v

2,6181,796

ROCE (%)

n/v

n/v

n/v

0.7-2.9

Financial Ratios (x) and Margin Analysis (%)

RatioFY2024FY2025

Net financial debt / EBITDA (x)

2.42.4

Capex / Sales (%)

5.55.9

FOCF conversion of EBITDA (%)

8.3-38.2

EBITDA / financial result coverage (x)

9.45.1

Revenue by Region

RegionFY2024FY2025

APAC sales (EUR Mn)

4,8244,383

EMLA plus NA sales combined (EUR Mn)

9,3558,559

Group sales (EUR Mn)

14,17912,942

Valuation Snapshot

MetricValue

IPO price (Oct 2015)

€24.00 (n/v)

Takeover offer

€62.00

Squeeze-out compensation

€59.46

Last traded range (spring 2026)

~€59.0–59.7

Dividend

Suspended since FY2022

Credit ratings

n/v (current)

Analyst Conclusions

FY2026 guidance: EBITDA significantly above €740m; FOCF and ROCE significantly better.

Bull: H1 2026 EBITDA +64%; XRG capital/feedstock; STRONG savings.

Bear: Chinese overcapacity; European cost base; execution/incident risk.

Catalysts: squeeze-out registration; Q3 2026 results; CEO successor; MDI program milestones.

Analyst verdict. Covestro has passed from public equity story to strategic asset. Its trough in 2025 — sales €12.9bn, EBITDA €740m, net loss €644m — was severe, but H1 2026 shows a sharp rebound (EBITDA €669m, net income €120m) and guidance was raised. Under XRG, the company gains capital, feedstock and Gulf growth options, while independence diminishes. The thesis now hinges on cyclical normalisation in MDI/PC, delivery of €400m STRONG savings, and integration into XRG. Minority investors are effectively exiting at €59.46; for creditors and counterparties, credit quality is supported by ownership.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleSinceBackground

Dr Markus Steilemann

CEO

CEO since 1 June 2018; Board member since 2015

Joined Bayer 1999, Bayer MaterialScience 2004; head of Polycarbonates 2013–2015; will not extend contract beyond 31 May 2028 (announced 23 Feb 2026)

Christian Baier

CFO (outgoing)

Oct 2023 – Sept 2026

Previously Metro AG (2011–2023), CFO from 2016; negotiated ADNOC premium and €1.2bn capital injection

Klaus Fröhlich

CFO (incoming)

From Oct 2026

Group Chief Investment Officer of ADNOC since 2020; formerly Morgan Stanley head of Middle East investment banking; led Covestro IPO for Bayer in 2015 at Morgan Stanley

Dr Thorsten Dreier

CTO & Labour Director

CTO since July 2023; Labour Director since Sept 2023; contract extended to 30 June 2031

Responsible for Engineering, Process Technology, HSE & Reliability, Procurement

Monique Buch

Chief Commercial Officer

Since Aug 2025

Succeeded Sucheta Govil

Major Shareholders

HolderStake

XRG P.J.S.C. (incl. ADNOC International Germany Holding AG)

~95.1% (Mar 2026); 100% upon registration of squeeze-out

Minority free float

~4.9% pending squeeze-out effectiveness

Insider ownership

Immaterial (n/v)

Competitive Landscape

Competitors by Segment

SegmentKey competitors

MDI/TDI/polyols

Wanhua Chemical, BASF, Dow, Huntsman, Tosoh, Kumho Mitsui, Sadara (Dow/Aramco)

Polycarbonate

SABIC, LG Chem, Lotte Chemical, Mitsubishi Chemical, Trinseo, Teijin, Chinese producers (Wanhua, etc.)

Aliphatic isocyanates / coatings resins

Vencorex (partly acquired), Asahi Kasei, Evonik, Wanhua, BASF, Allnex, Arkema

Peer Comparison FY2024

MetricCovestroBASFDowHuntsman

Sales FY2024 (bn, local currency)

14.2 EUR

65.3 EUR

43.0 USD

6.0 USD

EBITDA margin FY2024 (%)

7.6

n/v

n/v

n/v

Company Snapshot

$15,976.7M

Revenue

17,600

Employees

2005

Founded

Germany

Headquarters

SWOT Analysis

Strengths

  • Deep-pocketed owner: XRG (ADNOC) completed €1.17bn capital increase
  • Resilient specialty earnings: S&S EBITDA €681–817m FY2023–25
  • Cost discipline: STRONG: €275m savings by 2025 toward €400m by 2028
  • Global footprint: 46 sites; integrated hubs in DE, US, CN
  • Coatings leadership: Vencorex sites added July 2026; DSM RFM acquired 2021
  • Deleveraging: Net financial debt €1,796m (–31%) end-2025

Weaknesses

  • Earnings collapse: EBITDA €3,070m (2021) → €740m (2025)
  • Negative cash flow: FOCF –€283m FY2025
  • Repeated net losses: Net loss each year FY2022–FY2025
  • Operational incidents: Dormagen fire 2025; Rhine force majeure 2026
  • Negative ROCE: –2.9% FY2025
  • Forecast reliability: FY2025 EBITDA guidance cut from €1.0–1.6bn to €700–800m

Opportunities

  • Cyclical recovery: H1 2026 EBITDA +64%
  • Gulf capacity: MDI program incl. UAE
  • Circular economy: Sustainable Future strategy
  • XRG chemical platform: Covestro as foundational platform
  • Coatings growth: Vencorex acquisition
  • Leadership refresh: CEO succession process, new CFO

Threats

  • Chinese overcapacity: Price pressure across all regions (FY2025)
  • European energy cost: Structural disadvantage
  • Appraisal litigation: Spruchverfahren announced
  • Integration/governance risk: ADNOC-appointed CFO; minority protections lapse
  • Geopolitics/FSR: EU conditional clearance with commitments
  • Climate/logistics: Rhine low water 2026

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Q1 2025Q1 2025 EBITDA ~€137m (derived)Trough quarter
July 2025CTO Dreier contract extended to 2031Continuity in operations/transformation
July 2025Q2 2025: sales €3.4bn (–8.4%), EBITDA €270m, net –€59m, FOCF –€228mVolatile market
Aug 2025Monique Buch becomes CCOCommercial leadership change
Aug 2025Vencorex HDI sites agreementCoatings growth
H2 2025Dormagen chemical park fireMulti-plant outage, hundreds of €m impact
30 Oct 2025Q3 2025: sales €3.2bn (–12%), EBITDA €242m, FOCF €111m; FY guidance cut to €700–800mGuidance downgrade
Nov 2025EU conditional clearance of ADNOC dealFinal regulatory hurdle
Late 2025XRG closes takeover; €1.17bn capital increaseChange of control
9 Jan 2026Squeeze-out request (XRG 95.1%)Path to full ownership
Feb 2026Move to General StandardDelisting step
23 Feb 2026CEO will not renew beyond May 2028Succession process launched
~3 Mar 2026FY2025 results: sales €12.9bn, EBITDA €740m, net –€644m, FOCF –€283mWeak but within guidance
Mar 2026FY2026 outlook: EBITDA around prior-year levelStabilisation expected
20 Mar 2026Compensation €59.46/share (PwC)Below €62 offer
Apr/May 2026New credit facility arranged (details n/v)Liquidity under new ownership
~5 May 2026End of regulated-market listing (reported)Delisting
19 May 2026AGM approves squeeze-outFinal shareholder step
Post-May 2026Shareholder lawyers announce appraisal proceedingsPossible top-up payment risk for XRG
1 July 2026Vencorex Rayong & Freeport closingFootprint expansion
July 2026~660 kt MDI program China/UAECapacity growth
9 July 2026Prelim H1: sales €6,729m, EBITDA €669m; FY guidance raisedCyclical inflection
Summer 2026Rhine low water: force majeure on polyether polyols at DormagenLogistics risk
31 July 2026H1 2026 report; net income €120mReturn to profitability
31 July 2026CFO Baier departs Sept; Klaus Fröhlich (ADNOC CIO) from Oct 2026Integration into XRG
Oct 2026Fröhlich assumes CFO roleXRG influence on finance

Product Offering

  • Covestro AG
    • Product
    • Cast Elastomer
    • Polycarbonate panels
    • Global Textile Coatings

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment: Performance Materials sales fell from EUR 6,940 Mn in FY2024 to EUR 6,100 Mn in FY2025.
Covestro AG — Revenue by Segment
Series (EUR Mn)FY2023FY2024FY2025
Performance Materials sales—6,9406,100
Solutions & Specialties sales7,3007,0006,600
Group sales14,37714,17912,942

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.